Time of Metastatic Disease Presentation and Volume of Disease are Prognostic for Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

BACKGROUND: Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Prostate
Main Authors: Francini, Edoardo, Gray, Kathryn P., Xie, Wanling, Shaw, Grace K., Valença, Loana, Bernard, Brandon, Albiges, Laurence, Harshman, Lauren C., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Cristopher J.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171350/
https://ncbi.nlm.nih.gov/pubmed/29707790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23645
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares